Well, it says that the agreement is to 'develop classes'. I'm sure that's a timeframe of many months, if not a year. And, a curriculum that will evolve over time.
Still, this news along with the surgical tool manufacturer decision all make sense for a company planning well and moving in the right direction.
The bafflement (as always) is the share price and apparent lack of interest by the market, general or medically-focused. ISRG still has a monopoly on name recognition in surgical robotics.
Not much interest on Transenterix either.
News 
Market Data 
Discover 
AI
